Cinemark (CNK) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Zacks
02-17

The upcoming report from Cinemark Holdings (CNK) is expected to reveal quarterly earnings of $0.39 per share, indicating an increase of 360% compared to the year-ago period. Analysts forecast revenues of $797.34 million, representing an increase of 24.8% year over year.

Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 300% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.

Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.

Bearing this in mind, let's now explore the average estimates of specific Cinemark metrics that are commonly monitored and projected by Wall Street analysts.

The average prediction of analysts places 'Revenue- Admissions' at $398.54 million. The estimate points to a change of +23.6% from the year-ago quarter.

The collective assessment of analysts points to an estimated 'Revenue- Other' of $90.32 million. The estimate indicates a change of +22.9% from the prior-year quarter.

Analysts forecast 'Revenue- Concession' to reach $308.46 million. The estimate points to a change of +26.9% from the year-ago quarter.

According to the collective judgment of analysts, 'Revenue- International Operating Segment- Admissions' should come in at $66.53 million. The estimate points to a change of +21.2% from the year-ago quarter.

Based on the collective assessment of analysts, 'Revenue- U.S. Operating Segment- Admissions' should arrive at $330.50 million. The estimate points to a change of +23.6% from the year-ago quarter.

The consensus estimate for 'Revenue- International Operating Segment- Concession' stands at $50.77 million. The estimate indicates a year-over-year change of +20.6%.

The consensus among analysts is that 'Revenue- U.S. Operating Segment- Concession' will reach $257.03 million. The estimate indicates a year-over-year change of +27.9%.

The combined assessment of analysts suggests that 'Average ticket price - U.S. Operating Segment' will likely reach $10.06. The estimate is in contrast to the year-ago figure of $10.21.

Analysts' assessment points toward 'Average ticket price - International Operating Segment' reaching $3.72. Compared to the current estimate, the company reported $3.81 in the same quarter of the previous year.

Analysts expect 'Concession revenues per patron - U.S. Operating Segment' to come in at $7.82. The estimate compares to the year-ago value of $7.67.

Analysts predict that the 'Number of Screens - Total' will reach 5,789. Compared to the present estimate, the company reported 5,719 in the same quarter last year.

It is projected by analysts that the 'Attendance - U.S. Operating Segment' will reach 32.86 million. Compared to the current estimate, the company reported 26.2 million in the same quarter of the previous year.

View all Key Company Metrics for Cinemark here>>>

Over the past month, shares of Cinemark have returned +13.6% versus the Zacks S&P 500 composite's +4.7% change. Currently, CNK carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Cinemark Holdings Inc (CNK) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10